Regulator of G-protein signaling (RGS) proteins in cancer biology

Biochemical Pharmacology

Volumn 78, Issue 10, 2009, Pages 1289-1297

  Hurst, Jillian H ^a   Hooks, Shelley B ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Cancer; G protein coupled receptors; Regulator of G protein signaling proteins; Signal transduction

Indexed keywords

G PROTEIN COUPLED RECEPTOR; RGS PROTEIN;

ARTICLE; BLADDER CANCER; CANCER GROWTH; CARCINOGENESIS; HUMAN; LUNG CANCER; MULTIPLE CANCER; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 70349473057     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.06.028     Document Type: Note

References (123)

1. Pierce K.L., Premont R.T., and Lefkowitz R.J. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3 (2002) 639-650
2. Li S., Huang S., and Peng S.B. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 27 (2005) 1329-1339
3. Dorsam R.T., and Gutkind J.S. G-protein-coupled receptors and cancer. Nat Rev Cancer 7 (2007) 79-94
4. Spiegelberg B.D., and Hamm H.E. Roles of G-protein-coupled receptor signaling in cancer biology and gene transcription. Curr Opin Genet Dev 17 (2007) 40-44
5. Gutkind J.S. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 17 (1998) 1331-1342
6. Julius D., Livelli T.J., Jessell T.M., and Axel R. Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. Science 244 (1989) 1057-1062
7. Mills G.B., and Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3 (2003) 582-591
8. Bagnato A., and Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 40 (2008) 1443-1451
9. Rodien P., Ho S.C., Vlaeminck V., Vassart G., and Costagliola S. Activating mutations of TSH receptor. Ann Endocrinol (Paris) 64 (2003) 12-16
10. Arora P., Ricks T.K., and Trejo J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci 120 (2007) 921-928
11. Majima M., Amano H., and Hayashi I. Prostanoid receptor signaling relevant to tumor growth and angiogenesis. Trends Pharmacol Sci 24 (2003) 524-529
12. Rozengurt E., Guha S., and Sinnett-Smith J. Gastrointestinal peptide signalling in health and disease. Eur J Surg Suppl 587 (2002) 23-38
13. Kijima T., Maulik G., Ma P.C., Tibaldi E.V., Turner R.E., Rollins B., et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62 (2002) 6304-6311
14. Arvanitakis L., Geras-Raaka E., Varma A., Gershengorn M.C., and Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385 (1997) 347-350
15. Paulsen S.J., Rosenkilde M.M., Eugen-Olsen J., and Kledal T.N. Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J Virol 79 (2005) 536-546
16. Zhang H., Xu X., Gajewiak J., Tsukahara R., Fujiwara Y., Liu J., et al. Dual Activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 69 (2009) 5441-5449
17. Cao X., Qin J., Xie Y., Khan O., Dowd F., Scofield M., et al. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 25 (2006) 3719-3734
18. Biscardi J.S., Ishizawar R.C., Silva C.M., and Parsons S.J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2 (2000) 203-210
19. Burgess A.W. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 26 (2008) 263-274
20. Bennasroune A., Gardin A., Aunis D., Cremel G., and Hubert P. Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 50 (2004) 23-38
21. Zwick E., Bange J., and Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8 (2002) 17-23
22. Ciardiello F., and Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7 (2001) 2958-2970
23. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8 (2001) 3-9
24. Baselga J., and Hammond L.A. HER-targeted tyrosine-kinase inhibitors. Oncology 63 Suppl. 1 (2002) 6-16
25. Fischer O.M., Hart S., Gschwind A., and Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 31 (2003) 1203-1208
26. Vallar L., Spada A., and Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330 (1987) 566-568
27. Radhika V., and Dhanasekaran N. Transforming G proteins. Oncogene 20 (2001) 1607-1614
28. Lyons J., Landis C.A., Harsh G., Vallar L., Grunewald K., Feichtinger H., et al. Two G protein oncogenes in human endocrine tumors. Science 249 (1990) 655-659
29. Hermouet S., Aznavoorian S., and Spiegel A.M. In vitro and in vivo growth inhibition of murine melanoma K-1735 cell by a dominant negative mutant alpha subunit of the Gi2 protein. Cell Signal 8 (1996) 159-166
30. Sakai N., Kim K., Sanno N., Yoshida D., Teramoto A., and Shibasaki T. Elevation of growth hormone-releasing hormone receptor messenger ribonucleic acid expression in growth hormone-secreting pituitary adenoma with Gsalpha protein mutation. Neurol Med Chir (Tokyo) 48 (2008) 481-487 [discussion 7-8]
31. Landis C.A., Masters S.B., Spada A., Pace A.M., Bourne H.R., and Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340 (1989) 692-696
32. Kelly P., Casey P.J., and Meigs T.E. Biologic functions of the G12 subfamily of heterotrimeric g proteins: growth, migration, and metastasis. Biochemistry 46 (2007) 6677-6687
33. Chan A.M., Fleming T.P., McGovern E.S., Chedid M., Miki T., and Aaronson S.A. Expression cDNA cloning of a transforming gene encoding the wild-type G alpha 12 gene product. Mol Cell Biol 13 (1993) 762-768
34. Xu N., Bradley L., Ambdukar I., and Gutkind J.S. A mutant alpha subunit of G12 potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3 cells. Proc Natl Acad Sci U S A 90 (1993) 6741-6745
35. Worzfeld T., Wettschureck N., and Offermanns S. G(12)/G(13)-mediated signalling in mammalian physiology and disease. Trends Pharmacol Sci 29 (2008) 582-589
36. DeVivo M., and Iyengar R. G protein pathways: signal processing by effectors. Mol Cell Endocrinol 100 (1994) 65-70
37. Onken M.D., Worley L.A., Long M.D., Duan S., Council M.L., Bowcock A.M., et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49 (2008) 5230-5234
38. Posner B.A., Mukhopadhyay S., Tesmer J.J., Gilman A.G., and Ross E.M. Modulation of the affinity and selectivity of RGS protein interaction with G alpha subunits by a conserved asparagine/serine residue. Biochemistry 38 (1999) 7773-7779
39. Roy A.A., Baragli A., Bernstein L.S., Hepler J.R., Hebert T.E., and Chidiac P. RGS2 interacts with Gs and adenylyl cyclase in living cells. Cell Signal 18 (2006) 336-348
40. 2+ channel TRPV6. J Biol Chem 281 (2006) 29669-29674
41. Willard M.D., Willard F.S., Li X., Cappell S.D., Snider W.D., and Siderovski D.P. Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor-mediated differentiation. EMBO J 26 (2007) 2029-2040
42. Zhong H., Wade S.M., Woolf P.J., Linderman J.J., Traynor J.R., and Neubig R.R. A spatial focusing model for G protein signals. Regulator of G protein signaling (RGS) protein-mediated kinetic scaffolding. J Biol Chem 278 (2003) 7278-7284
43. Chen C.K., Burns M.E., He W., Wensel T.G., Baylor D.A., and Simon M.I. Slowed recovery of rod photoresponse in mice lacking the GTPase accelerating protein RGS9-1. Nature 403 (2000) 557-560
44. Heximer S.P., Knutsen R.H., Sun X., Kaltenbronn K.M., Rhee M.H., Peng N., et al. Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. J Clin Invest 111 (2003) 1259
45. Zeng W., Xu X., Popov S., Mukhopadhyay S., Chidiac P., Swistok J., et al. The N-terminal domain of RGS4 confers receptor-selective inhibition of G protein signaling. J Biol Chem 273 (1998) 34687-34690
46. Kimple R.J., De Vries L., Tronchere H., Behe C.I., Morris R.A., Gist Farquhar M., et al. RGS12 and RGS14 GoLoco motifs are G alpha(i) interaction sites with guanine nucleotide dissociation inhibitor activity. J Biol Chem 276 (2001) 29275-29281
47. Bernstein L.S., Ramineni S., Hague C., Cladman W., Chidiac P., Levey A.I., et al. RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling. J Biol Chem 279 (2004) 21248-21256
48. Hollinger S., and Hepler J.R. Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol Rev 54 (2002) 527-559
49. Oliveira-Dos-Santos A.J., Matsumoto G., Snow B.E., Bai D., Houston F.P., Whishaw I.Q., et al. Regulation of T cell activation, anxiety, and male aggression by RGS2. Proc Natl Acad Sci U S A 97 (2000) 12272-12277
50. Grillet N., Pattyn A., Contet C., Kieffer B.L., Goridis C., and Brunet J.F. Generation and characterization of Rgs4 mutant mice. Mol Cell Biol 25 (2005) 4221-4228
51. Nisancioglu M.H., Mahoney Jr. W.M., Kimmel D.D., Schwartz S.M., Betsholtz C., and Genove G. Generation and characterization of rgs5 mutant mice. Mol Cell Biol 28 (2008) 2324-2331
52. Hurst J.H., Henkel P.A., Brown A.L., and Hooks S.B. Endogenous RGS proteins attenuate Galpha(i)-mediated lysophosphatidic acid signaling pathways in ovarian cancer cells. Cell Signal 20 (2008) 381-389
53. Hurst J.H., Mendpara N., and Hooks S.B. Regulator of G-protein signaling expression and function in ovarian cancer cell lines. Cell Mol Biol Lett 14 (2008) 153-174
54. Grunebach F., Erndt S., Hantschel M., Heine A., and Brossart P. Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells. Cancer Immunol Immunother 57 (2008) 1483-1491
55. Rangel J., Nosrati M., Leong S.P., Haqq C., Miller III J.R., Sagebiel R.W., et al. Novel role for RGS1 in melanoma progression. Am J Surg Pathol 32 (2008) 1207-1212
56. Furuya M., Nishiyama M., Kimura S., Suyama T., Naya Y., Ito H., et al. Expression of regulator of G protein signalling protein 5 (RGS5) in the tumour vasculature of human renal cell carcinoma. J Pathol 203 (2004) 551-558
57. Rae F.K., Stephenson S.A., Nicol D.L., and Clements J.A. Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer 88 (2000) 726-732
58. Han J.I., Huang N.N., Kim D.U., and Kehrl J.H. RGS1 and RGS13 mRNA silencing in a human B lymphoma line enhances responsiveness to chemoattractants and impairs desensitization. J Leukoc Biol 79 (2006) 1357-1368
59. Islam T.C., Asplund A.C., Lindvall J.M., Nygren L., Liden J., Kimby E., et al. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 17 (2003) 1880-1890
60. Tsai C.C., Huang K.W., Chen H.F., Zhan B.W., Lai Y.H., Lee F.H., et al. Gene expression analysis of human hepatocellular carcinoma by using full-length cDNA library. J Biomed Sci 13 (2006) 241-249
61. Chen X., Higgins J., Cheung S.T., Li R., Mason V., Montgomery K., et al. Novel endothelial cell markers in hepatocellular carcinoma. Mod Pathol 17 (2004) 1198-1210
62. Silva A.P., Salim A.C., Bulgarelli A., de Souza J.E., Osorio E., Caballero O.L., et al. Identification of 9 novel transcripts and two RGSL genes within the hereditary prostate cancer region (HPC1) at 1q25. Gene 310 (2003) 49-57
63. Sood R., Bonner T.I., Makalowska I., Stephan D.A., Robbins C.M., Connors T.D., et al. Cloning and characterization of 13 novel transcripts and the human RGS8 gene from the 1q25 region encompassing the hereditary prostate cancer (HPC1) locus. Genomics 73 (2001) 211-222
64. Wiechec E., Overgaard J., and Hansen L.L. A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas. Genes Chromosomes Cancer 47 (2008) 766-780
65. Smalley M.J., Iravani M., Leao M., Grigoriadis A., Kendrick H., Dexter T., et al. Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. Breast Cancer Res 9 (2007) R85
66. Nikolova D.N., Zembutsu H., Sechanov T., Vidinov K., Kee L.S., Ivanova R., et al. Genome-wide gene expression profiles of thyroid carcinoma: identification of molecular targets for treatment of thyroid carcinoma. Oncol Rep 20 (2008) 105-121
67. Tonjes A., Miedlich S., Holzapfel H.P., Eszlinger M., Arkenau C., and Paschke R. Expression of regulators of g protein signaling mRNA is differentially regulated in hot and cold thyroid nodules. Thyroid 14 (2004) 896-901
68. Hamzah J., Jugold M., Kiessling F., Rigby P., Manzur M., Marti H.H., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453 (2008) 410-414
69. Schwable J., Choudhary C., Thiede C., Tickenbrock L., Sargin B., Steur C., et al. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation. Blood 105 (2005) 2107-2114
70. Koga H., Imada K., Ueda M., Hishizawa M., and Uchiyama T. Identification of differentially expressed molecules in adult T-cell leukemia cells proliferating in vivo. Cancer Sci 95 (2004) 411-417
71. Tatenhorst L., Senner V., Puttmann S., and Paulus W. Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility. J Neuropathol Exp Neurol 63 (2004) 210-222
72. Pospisil H., Herrmann A., Butherus K., Pirson S., Reich J.G., and Kemmner W. Verification of predicted alternatively spliced Wnt genes reveals two new splice variants (CTNNB1 and LRP5) and altered Axin-1 expression during tumour progression. BMC Genomics 7 (2006) 148
73. Whibley C., Pharoah P.D., and Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 9 (2009) 95-107
74. Pao W., and Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23 (2005) 2556-2568
75. Chowdari K.V., Bamne M., Wood J., Talkowski M.E., Mirnics K., Levitt P., et al. Linkage disequilibrium patterns and functional analysis of RGS4 polymorphisms in relation to schizophrenia. Schizophr Bull 34 (2008) 118-126
76. Smoller J.W., Paulus M.P., Fagerness J.A., Purcell S., Yamaki L.H., Hirshfeld-Becker D., et al. Influence of RGS2 on anxiety-related temperament, personality, and brain function. Arch Gen Psychiatry 65 (2008) 298-308
77. Hunt K.A., Zhernakova A., Turner G., Heap G.A., Franke L., Bruinenberg M., et al. Newly identified genetic risk variants for celiac disease related to the immune response. Nat Genet 40 (2008) 395-402
78. Gu J., Wu X., Dong Q., Romeo M.J., Lin X., Gutkind J.S., et al. A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. Cancer 106 (2006) 2716-2724
79. Lee E.S., Roberts R.E., and Labarthe D.R. Excess and deficit lung cancer mortality in three ethnic groups in Texas. Cancer 38 (1976) 2551-2556
80. Berman D.M., Wang Y., Liu Z., Dong Q., Burke L.A., Liotta L.A., et al. A functional polymorphism in RGS6 modulates the risk of bladder cancer. Cancer Res 64 (2004) 6820-6826
81. Zhu Y., Hollmen J., Raty R., Aalto Y., Nagy B., Elonen E., et al. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol 119 (2002) 905-915
82. Collier L.S., and Largaespada D.A. Transposons for cancer gene discovery: sleeping beauty and beyond. Genome Biol 8 Suppl. 1 (2007) S15
83. Qin L.X. Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol 8 (2002) 769-776
84. Gilliland D.G., and Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 100 (2002) 1532-1542
85. Burridge K., and Wennerberg K. Rho and Rac take center stage. Cell 116 (2004) 167-179
86. Schmitz A.A., Govek E.E., Bottner B., and Van Aelst L. Rho GTPases: signaling, migration, and invasion. Exp Cell Res 261 (2000) 1-12
87. Vega F.M., and Ridley A.J. Rho GTPases in cancer cell biology. FEBS Lett 582 (2008) 2093-2101
88. Fukuhara S., Chikumi H., and Gutkind J.S. RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho?. Oncogene 20 (2001) 1661-1668
89. Wang Q., Liu M., Kozasa T., Rothstein J.D., Sternweis P.C., and Neubig R.R. Thrombin and lysophosphatidic acid receptors utilize distinct rhoGEFs in prostate cancer cells. J Biol Chem 279 (2004) 28831-28834
90. Chikumi H., Barac A., Behbahani B., Gao Y., Teramoto H., Zheng Y., et al. Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential. Oncogene 23 (2004) 233-240
91. Salahshor S., and Woodgett J.R. The links between axin and carcinogenesis. J Clin Pathol 58 (2005) 225-236
92. Nelson W.J., and Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 303 (2004) 1483-1487
93. Peifer M., and Polakis P. Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science 287 (2000) 1606-1609
94. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., and Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310 (2005) 1504-1510
95. Stemmle L.N., Fields T.A., and Casey P.J. The regulator of G protein signaling domain of axin selectively interacts with Galpha12 but not Galpha13. Mol Pharmacol 70 (2006) 1461-1468
96. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
97. Manzur M., Hamzah J., and Ganss R. Modulation of g protein signaling normalizes tumor vessels. Cancer Res 69 (2009) 396-399
98. Boss C.N., Grunebach F., Brauer K., Hantschel M., Mirakaj V., Weinschenk T., et al. Identification and characterization of T-cell epitopes deduced from RGS5, a novel broadly expressed tumor antigen. Clin Cancer Res 13 (2007) 3347-3355
99. James M.A., Lu Y., Liu Y., Vikis H.G., and You M. RGS17, an overexpressed gene in human lung and prostate cancer, induces tumor cell proliferation through the cyclic AMP-PKA-CREB pathway. Cancer Res 69 (2009) 2108-2116
100. Feigin M.E., and Malbon C.C. RGS19 regulates Wnt-beta-catenin signaling through inactivation of Galpha(o). J Cell Sci 120 (2007) 3404-3414
101. Kirikoshi H., and Katoh M. Expression of human GIPC1 in normal tissues, cancer cell lines, and primary tumors. Int J Mol Med 9 (2002) 509-513
102. Riker A.I., Enkemann S.A., Fodstad O., Liu S., Ren S., Morris C., et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1 (2008) 13
103. Liu C.J., Liu T.Y., Kuo L.T., Cheng H.W., Chu T.H., Chang K.W., et al. Differential gene expression signature between primary and metastatic head and neck squamous cell carcinoma. J Pathol 214 (2008) 489-497
104. Wong Y.F., Cheung T.H., Tsao G.S., Lo K.W., Yim S.F., Wang V.W., et al. Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int J Cancer 118 (2006) 2461-2469
105. Kannangai R., Vivekanandan P., Martinez-Murillo F., Choti M., and Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol 38 (2007) 639-644
106. Ooe A., Kato K., and Noguchi S. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 101 (2007) 305-315
107. Takahashi H., Nemoto T., Yoshida T., Honda H., and Hasegawa T. Cancer diagnosis marker extraction for soft tissue sarcomas based on gene expression profiling data by using projective adaptive resonance theory (PART) filtering method. BMC Bioinformatics 7 (2006) 399
108. Chng W.J., Remstein E.D., Fonseca R., Bergsagel P.L., Vrana J.A., Kurtin P.J., et al. Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. Blood 113 (2009) 635-645
109. Davidsson J., Andersson A., Paulsson K., Heidenblad M., Isaksson M., Borg A., et al. Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3. Hum Mol Genet 16 (2007) 2215-2225
110. Fevre-Montange M., Champier J., Szathmari A., Wierinckx A., Mottolese C., Guyotat J., et al. Microarray analysis reveals differential gene expression patterns in tumors of the pineal region. J Neuropathol Exp Neurol 65 (2006) 675-684
111. Buckbinder L., Velasco-Miguel S., Chen Y., Xu N., Talbott R., Gelbert L., et al. The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc Natl Acad Sci U S A 94 (1997) 7868-7872
112. Martinez-Cardus A., Martinez-Balibrea E., Bandres E., Malumbres R., Gines A., Manzano J.L., et al. Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Mol Cancer Ther 8 (2009) 194-202
113. Pan K.F., Liu W.G., Zhang L., You W.C., and Lu Y.Y. Mutations in components of the Wnt signaling pathway in gastric cancer. World J Gastroenterol 14 (2008) 1570-1574
114. Ishizaki Y., Ikeda S., Fujimori M., Shimizu Y., Kurihara T., Itamoto T., et al. Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol 24 (2004) 1077-1083
115. Tokumoto N., Ikeda S., Ishizaki Y., Kurihara T., Ozaki S., Iseki M., et al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol 27 (2005) 973-980
116. Daa T., Kashima K., Kaku N., Suzuki M., and Yokoyama S. Mutations in components of the Wnt signaling pathway in adenoid cystic carcinoma. Mod Pathol 17 (2004) 1475-1482
117. Baeza N., Masuoka J., Kleihues P., and Ohgaki H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 22 (2003) 632-636
118. Iwai S., Katagiri W., Kong C., Amekawa S., Nakazawa M., and Yura Y. Mutations of the APC, beta-catenin, and axin 1 genes and cytoplasmic accumulation of beta-catenin in oral squamous cell carcinoma. J Cancer Res Clin Oncol 131 (2005) 773-782
119. Jin L.H., Shao Q.J., Luo W., Ye Z.Y., Li Q., and Lin S.C. Detection of point mutations of the Axin1 gene in colorectal cancers. Int J Cancer 107 (2003) 696-699
120. Xu H.T., Wang L., Lin D., Liu Y., Liu N., Yuan X.M., et al. Abnormal beta-catenin and reduced axin expression are associated with poor differentiation and progression in non-small cell lung cancer. Am J Clin Pathol 125 (2006) 534-541
121. Steg A., Wang W., Blanquicett C., Grunda J.M., Eltoum I.A., Wang K., et al. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn 8 (2006) 76-83
122. Roh M.S., Hong S.H., Jeong J.S., Kwon H.C., Kim M.C., Cho S.H., et al. Gene expression profiling of breast cancers with emphasis of beta-catenin regulation. J Korean Med Sci 19 (2004) 275-282
123. Dahmen R.P., Koch A., Denkhaus D., Tonn J.C., Sorensen N., Berthold F., et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 61 (2001) 7039-7043